South Korean Study Also Shows Mixed Regime Of COVID-19 Jabs Boosts Antibody Levels: Reuters

A South Korean study, mixed vaccination of first AstraZeneca plc’s AZN jab followed by the Pfizer Inc PFE - BioNTech SE BNTX shot boosted antibody levels by at least six times, Reuters reported Monday.
The shots were up against a double dose of AstraZeneca in the study.
Of the 499 medical workers, 100 received mixed doses, and 200 received just the Pfizer-BioNTech jab.
The mixed schedule of vaccines showed similar amounts of neutralizing antibodies found from the group that received two Pfizer shots.
Last month, the U.K. study showed similar results, when AstraZeneca shot followed by Pfizer showed the best T cell responses and a higher antibody response than Pfizer followed by AstraZeneca’s.
Volunteers that received a mixed regime showed neutralizing antibodies, which stop the virus from entering cells.
The study analyzed activity against variants and saw that neutralization was decreased against the Beta, Gamma, and Delta variants.
All three groups maintained the same neutralizing activity against the Alpha variant.
Price Action: PFE shares are up 0.29% at $41.80, BNTX stock is +0.57% at $282.61, while AZN shares are down 2.31% at $56.89 during the market session the last check Monday.
Photo by Daniel Schludi on Unsplash